Mabworks Biotech Overview
- Year Founded
-
2003
- Status
-
Private
- Employees
-
277
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
19
- Investments
-
1
Mabworks Biotech General Information
Description
Developer of differential antibody drugs to serve cancer biology. The company specializes in developing pre-clinical and clinical tumor and autoimmune diseases-related drugs by translating the scientific breakthrough of immunology and cancer biology, providing research and pharmaceutical support for treating diseases.
Contact Information
Website
www.mab-works.comCorporate Office
- Room 2505, Building 1, Yard 2, Ronghua South Road
- Beijing Economic and Technological Development Zone
- Beijing, 100176
- China
Corporate Office
- Room 2505, Building 1, Yard 2, Ronghua South Road
- Beijing Economic and Technological Development Zone
- Beijing, 100176
- China
Mabworks Biotech Timeline
Mabworks Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mabworks Biotech Comparisons
Industry
Financing
Details
Mabworks Biotech Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| CureGenetics | Venture Capital-Backed | Suzhou, China | ||||
| BeiGene | Formerly PE-Backed | Cambridge, MA | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA |
Mabworks Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mabworks Biotech Patents
Mabworks Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240084027-A1 | Antibodies binding cd40 and pd-l1 and uses thereof | Pending | 26-Aug-2022 | ||
| US-20230382995-A1 | Molecules binding pd-l1 and uses thereof | Pending | 31-May-2022 | ||
| US-20230348630-A1 | Antibodies binding bcma and cd3 and uses thereof | Active | 28-Apr-2022 | ||
| US-20230348629-A1 | Bispecific molecules binding tigit and vegf and uses thereof | Pending | 28-Apr-2022 | ||
| US-20230348612-A1 | Single-chain fragment variable comprising mutant light chain framework region | Pending | 28-Apr-2022 | C07K16/2887 |
Mabworks Biotech Executive Team (6)
| Name | Title | Board Seat |
|---|---|---|
| Feng Li Ph.D | Founder, Chairman & General Manager | |
| Jinjin Liang | Chief Medical Officer and Deputy General Manager | |
| Huifang Liu | Deputy General Manager (Translational Medicine and Regulatory Affairs) | |
| Wenqi Hu | Deputy General Manager (Antibody Discovery & Board Member |
Mabworks Biotech Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Mabworks Biotech | Founder, Chairman & General Manager | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Mabworks Biotech | Deputy General Manager (Antibody Discovery & Board Member |
Mabworks Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mabworks Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mabworks Biotech Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Duoning Biotechnology | 18-Jul-2018 | Medical Supplies |
Mabworks Biotech FAQs
-
When was Mabworks Biotech founded?
Mabworks Biotech was founded in 2003.
-
Who is the founder of Mabworks Biotech?
Feng Li Ph.D is the founder of Mabworks Biotech.
-
Where is Mabworks Biotech headquartered?
Mabworks Biotech is headquartered in Beijing, China.
-
What is the size of Mabworks Biotech?
Mabworks Biotech has 277 total employees.
-
What industry is Mabworks Biotech in?
Mabworks Biotech’s primary industry is Drug Discovery.
-
Is Mabworks Biotech a private or public company?
Mabworks Biotech is a Private company.
-
What is the current valuation of Mabworks Biotech?
The current valuation of Mabworks Biotech is .
-
What is Mabworks Biotech’s current revenue?
The current revenue for Mabworks Biotech is .
-
How much funding has Mabworks Biotech raised over time?
Mabworks Biotech has raised $333M.
-
Who are Mabworks Biotech’s investors?
CGP Investment, Jiangsu Hengrui Pharmaceuticals, China Lesso Group, Hangzhou Tigermed Consulting Company, and Ally Bridge Group are 5 of 28 investors who have invested in Mabworks Biotech.
-
Who are Mabworks Biotech’s competitors?
CytomX Therapeutics, BioNTech, CureGenetics, BeiGene, and Sutro Biopharma are some of the 17 competitors of Mabworks Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
